A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome

Clinical Trials

Volumn 4, Issue 2, 2007, Pages 140-153

  Zhao, Yanli ^a   Grambsch, Patricia M ^b   Neaton, James D ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD;

CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DECISION MAKING; HUMANS; SAFETY; TREATMENT OUTCOME;

EID: 34249290790     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507076936     Document Type: Article

References (35)

1. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40: 1079-1087.
2. Tang D, Gnecco C, Geller NL. Design of group sequential clinical trials with multiple endpoints. J Am Stat Assoc 1989; 84: 776-779.
3. Tang D, Geller NL, Pocock SJ. On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 1993; 49: 23-30.
4. Jennison C, Turnbull BW. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 1993; 49: 741-52.
5. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Chapman & Hall/CRC, 2000.
6. Todd S. Sequential designs for monitoring two endpoints in a clinical trial. Drug Inform J 1999; 33: 417-26.
7. Cook RJ, Farewell VT. Guidelines for monitoring efficacy and toxicity responses in clinical trials. Biometrics 1994; 50: 1146-52.
8. Cook RJ. Interim monitoring of bivariate responses using repeated confidence intervals. Cont Clin Trials, 1994; 1: 187-200.
9. Cook RJ. Coupled error spending functions for parallel bivariate sequential tests. Biometrics 1996; 52: 442-50.
10. Chen YH, DeMets DL, Lan KKG. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Cont Clin Trials 2003; 24: 16-27.
11. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
12. Women's Health initiative manuals, vol 1. Study protocol and policies. WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Version 1.0, September 1, Seattle, WA, 1994.
13. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.
14. Freedman LS, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Cont Clin Trials 1996; 17: 509-25.
15. Prentice RL. Discussion: On the role and analysis of secondary outcomes in clinical trials. Cont Clin Trials 1997; 18: 561-7.
16. Prentice RL, Anderson G, Cummings S, et al. Design of the Women's Health Initiative Clinical Trial and Observational Study. Cont Clin Trials 1998; 19: 61-109.
17. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. New England J Med 2006; 355: 2283-96.
18. Capizzi T, Zhang J. Testing the hypothesis that matters for multiple primary endpoints. Drug Inform J 1996; 30: 949-56.
19. O'Brien PC, Fleming RT. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
20. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
21. Hougaard P. A class of multivariate failure time distributions. Biometrika 1986; 73(3): 671-8.
22. Tang DI, Geller NL. Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics 1999; 55(4): 1188-92.
23. Kosorok MR, Shi YJ, DeMets DL. Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics 2004; 60: 134-45.
24. Montori VM, Devereaux PJ. Randomized trials stopped early for benefit. A systematic review. JAMA 2005; 294(17): 2203-9.
25. Bristol DR. Superior safety in noninferiority trials. Biomet J 2005; 47: 75-81.
26. Senn S. 'Equivalence is Different' - some comments on therapeutic equivalence. Biomet J 2005; 47: 104-7.
27. Bauer P. Therapeutic equivalence - some comments. Biomet J 2005; 47: 99-103.
28. Braunwald E, Cannon CP, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction - the 'unsatisfactory outcome' end point. Circulation 1992; 86(2): 683-7.
29. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998; 17: 1563-80.
30. Thall PF, Simon R, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995; 14: 357-79.
31. Conaway MR, Petroni GR. Designs for phase II trials allowing for a trade-off between response and toxicity. Biometrics 1996; 52: 1375-86.
32. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51: 1372-83.
33. Etzioni R, Pepe M. Monitoring of a pilot toxicity study with two adverse outcomes. Stat Med, 1994; 13: 2311-22.
34. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials, (with discussion). J Roy Stat Soc A 1994; 157: 357-416.
35. The Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: the Coronary Drug Project as a case study. Cont Clin Trials 1981; 1: 363-76.